Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 2, 2001 |
| Grant date | Jun 26, 2007 |
| Priority date | — |
| Expiry date | Sep 6, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/446
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods of treating or preventing vascular diseases caused by nitric oxide (NO) insufficiency. The methods encompass administering a composition comprising an antioxidant, a compound to treat cardiovascular diseases, a nitrosated compound, a compound that donates, transfers or relases NO, or is a NO synthase substrate, or endogenously stimulates NO synthesis, or stimulates levels of endothelium derived relaxing factor. In the said composition, a hydralazine compound may be an antioxidant, isosorbide mono-or dinitrate may be the compound to donate, transfer, release, or stimulate endogenous NO synthesis. The isorsorbide may also elevate endogenous levels of endotherlium-derived relaxing factor, or be a NO synthase substrate and angiotensin enzyme inhibitor may be nitrosated compound. Disclosed in the invention is also a method to treat, or prevent Renaud's syndrome by administering a therapeutically effective amount of an antioxidant, a NO donor, a nitrosated compound and novel sustained-release formulations (e.g. a transdermal patch).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.